Burst Biologics Foot and Ankle Registry
Purpose
This prospective registry was designed as an observational study to ascertain how commercially available Burst Products are being used by foot and ankle surgeons performing procedures which involve bone grafting, as well as determining relevant patient outcomes.
Conditions
- Foot and Ankle Disorders
- Ankle Fusion, Osteotomy
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patient aged 18 years or older - Patient diagnosed with a pathology of the hindfoot, foot, or ankle requiring surgical intervention. - The surgeon has determined that a Burst Biologic product is or was clinically indicated. - Patient capable of understanding the content of the Informed Consent Form. - Patient willing and able to participate in the registry protocol including the surgeon's standard follow-up visits and clinical evaluations. - Patient who has agreed to participate in the registry by providing consent per the applicable local law and the declaration of Helsinki.
Exclusion Criteria
The following are relative contraindications for the use of Burst Products, however the investigator surgeon is solely responsible for the determination of patient eligibility for surgery: - Severe vascular or neurological disease - Uncontrolled diabetes - Severe degenerative disease (other than degenerative disc disease) - Hypercalcemia, abnormal calcium metabolism - Existing acute or chronic infections, especially at the site of the operation - Inflammatory bone disease such as osteomyelitis - Malignant tumors - Patients who are or plan to become pregnant.
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Recruiting Locations
Washington, District of Columbia 20007
Paul S Cooper, MD
More Details
- Status
- Unknown status
- Sponsor
- Burst Biologics
Detailed Description
Foot and ankle surgery requiring the use of bone graft is common despite recent advancements and improved outcomes with new motion preservation devices (ankle replacement). Autogenous bone remains the gold standard but is complicated by donor site morbidity and availability of a sufficient volume of graft. Over the past two decades surgeon interest in alternative bone grafts has steadily increased. Bone morphogenic proteins, synthetic bone graft substitutes, and various allograft products are widely available to surgeons. Limitations on the use of allografts in the past were mainly attributed to less than optimal donor screening and processing techniques which removed viable components needed to aid in the bone healing process. In recent years, the focus and scientific advances in various allograft processing techniques have allowed the retention of various viable cytokines, growth factors, and cell populations which result in enhanced osteogenic and osteoinductive properties. Rigorous donor bone screening and meticulous testing has virtually eliminated the risk of disease transmission. A unique proprietary cryoprotection processing technique for allograft tissue was developed by Smart-Surgical, Inc. and a complete line of allograft products was created and is now marketed by Burst Biologics (dba). In addition, rigorous standardized laboratory assay techniques and statistical analysis provide consistency and uniformity of the biologically active components of Burst allograft products. This prospective registry was designed as an observational study to ascertain how commercially available Burst Products are being used by foot and ankle surgeons performing procedures which involve bone grafting, as well as determining relevant patient outcomes.